- Company
- Why MSD raised the price of Gardasil 9 for two years?
- by May 17, 2022 06:02am
- As MSD Korea raised the supply price of Gardasil 9, a cervical cancer vaccine, by 25% in two years, attention is being paid to the background. Some interpret the decision ahead of the application of Gadasil 9's health insurance benefits, which was President Yoon Seok-yeol's pledge, or an alternative to fill the sales gap due to the reduction
- Company
- Prescription of CGRP migraine drugs to begin in earnest?
- by Eo, Yun-Ho May 17, 2022 06:01am
- CGRP-targeted migraine treatments are gaining better access as prescriptions. The first drug introduced is nearing insurance benefit listing and the second drug is landing in general hospitals. According to industry sources, the Calcitonin gene-related peptide (CGRP)-targeted migraine treatment ‘Emgality (galcanezumab)’ has passed delib
- Company
- Servier launches supply of new acute leukemia drug Oncaspar
- by Eo, Yun-Ho May 16, 2022 06:14am
- Servier Korea began supplying Oncaspar Lyophilized Inj, a combination treatment for "acute lymphocytic leukemia (ALL)" from the 10th. It was supplied through the rare drug center, but the license holder, Servier, was in charge of the supply, and insurance benefits have not yet been registered. Servier Korea is undergoing prescription procedur
- Company
- Huons' local anesthetics export contract with FPI Canada
- by Kim, Jin-Gu May 16, 2022 06:14am
- Huons announced on the 13th that it has signed an export contract with Canadian pharmaceutical company Formative Pharma Inc (FPI). Items signed an export contract are▲1% Lidocaine hydrochloride injection 5mL, ▲ 0.75% Bupivacaine hydrochloride injection 2ml, and ▲ 1% lidocaine hydrochloride injection 5mL vial. These items were obtained from
- Company
- The introduction of Biogen Aduhelm in Korea is also unclear
- by May 16, 2022 06:13am
- Biogen has decided to minimize the commercialization infrastructure of the Alzheimer's drug Aduhelm and focus on developing subsequent drugs. In fact, it is unclear whether Aduhelm, which is in the process of eviction, will be introduced in Korea. Biogen announced in its first-quarter earnings announcement on the 3rd (local time) that CEO
- Company
- Wet AMD tx new option to shorten Eyelea's minimum cycle
- by May 16, 2022 06:13am
- Bayer's macular degeneration treatment Eyelea took the lead in establishing an optimized treatment strategy for patients by shortening the minimum treatment cycle. It is evaluated that a new option was presented in macular degeneration treatment that determines the treatment cycle according to the patient's condition. According to the phar
- Company
- Bio Clusters gather to compete at BIO Korea 2022
- by Kim, Jin-Gu May 13, 2022 05:46am
- Major Bio Clusters of local governments have gathered in one place. Major Bio Clusters of local governments including Osong, Incheon, Hongneung, Gimhae, Wonju, and Daejeon municipalities as well as the event’s co-host Chungcheongbuk-do are in heated competition to promote their cluster in the ‘BIO KOREA 2022’ event that is being held f
- Company
- Lumakras is a new opportunity for lung cancer patients
- by May 13, 2022 05:45am
- "Lumakras is the first-in-class and best-in-class for patients with KRAS G12C mutated non-small cell lung cancer who failed existing treatment. The reliability of drugs has also increased over the past two years with long-term data, and it is expected that they may be used in combination with other drugs such as immuno-cancer drugs in the future
- Company
- LG Chem’s partner enters Phase I trial on its immunotherapy
- by Kim, Jin-Gu May 13, 2022 05:45am
- On the 12th, Cue Biopharma, LG Chem’s partner in developing a cancer immunotherapy, announced it had won FDA approval to initiate Phase 1 clinical trials for ‘CUE-102 .’ LG Chem has exclusive rights to develop and market the candidate in 11 Asian countries including Korea, China, and Japan. With the trial approval, Cue Biopharma wil
- Company
- K-Cab & Fexuclu are quickly targeting the global market
- by Chon, Seung-Hyun May 12, 2022 06:07am
- New drug products developed by domestic pharmaceutical companies with their own technologies are accelerating their targeting in the global market. However, some point out that it is difficult to predict commercial success because there are many variables such as the situation of the local market even if they have reserved to enter the overse
